Literature DB >> 3521194

Migraine treatment with calcium channel blockers.

K E Andersson, L Brandt, B Hindfelt, T Ryman.   

Abstract

Irrespective of their mechanism of action, which so far has not been clarified, calcium channel blockers (CCBs) have a documented prophylactic effect on classical and common migraine, as well as on cluster headache. The drugs may reduce migraine prodromes, the frequency of migraine attacks, and also decrease the severity and possibly the duration of these attacks. Notably, their optimum effect is often seen after more than 2 months of treatment. Side effects seem to be few and mild. Whether or not there are differences in therapeutic efficacy between different CCBs is presently unclear. As comparisons with other alternatives of treatment are sparse, the place of CCBs in migraine therapy remains to be established.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3521194     DOI: 10.1111/j.1600-0773.1986.tb02532.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  2 in total

1.  Depression associated with diltiazem.

Authors:  C Biriell; J McEwen; E Sanz
Journal:  BMJ       Date:  1989-09-23

2.  Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion.

Authors:  Isabelle Cleynen; Worrawat Engchuan; Matthew S Hestand; Tracy Heung; Aaron M Holleman; H Richard Johnston; Thomas Monfeuga; Donna M McDonald-McGinn; Raquel E Gur; Bernice E Morrow; Ann Swillen; Jacob A S Vorstman; Carrie E Bearden; Eva W C Chow; Marianne van den Bree; Beverly S Emanuel; Joris R Vermeesch; Stephen T Warren; Michael J Owen; Pankaj Chopra; David J Cutler; Richard Duncan; Alex V Kotlar; Jennifer G Mulle; Anna J Voss; Michael E Zwick; Alexander Diacou; Aaron Golden; Tingwei Guo; Jhih-Rong Lin; Tao Wang; Zhengdong Zhang; Yingjie Zhao; Christian Marshall; Daniele Merico; Andrea Jin; Brenna Lilley; Harold I Salmons; Oanh Tran; Peter Holmans; Antonio Pardinas; James T R Walters; Wolfram Demaerel; Erik Boot; Nancy J Butcher; Gregory A Costain; Chelsea Lowther; Rens Evers; Therese A M J van Amelsvoort; Esther van Duin; Claudia Vingerhoets; Jeroen Breckpot; Koen Devriendt; Elfi Vergaelen; Annick Vogels; T Blaine Crowley; Daniel E McGinn; Edward M Moss; Robert J Sharkus; Marta Unolt; Elaine H Zackai; Monica E Calkins; Robert S Gallagher; Ruben C Gur; Sunny X Tang; Rosemarie Fritsch; Claudia Ornstein; Gabriela M Repetto; Elemi Breetvelt; Sasja N Duijff; Ania Fiksinski; Hayley Moss; Maria Niarchou; Kieran C Murphy; Sarah E Prasad; Eileen M Daly; Maria Gudbrandsen; Clodagh M Murphy; Declan G Murphy; Antonio Buzzanca; Fabio Di Fabio; Maria C Digilio; Maria Pontillo; Bruno Marino; Stefano Vicari; Karlene Coleman; Joseph F Cubells; Opal Y Ousley; Miri Carmel; Doron Gothelf; Ehud Mekori-Domachevsky; Elena Michaelovsky; Ronnie Weinberger; Abraham Weizman; Leila Kushan; Maria Jalbrzikowski; Marco Armando; Stéphan Eliez; Corrado Sandini; Maude Schneider; Frédérique Sloan Béna; Kevin M Antshel; Wanda Fremont; Wendy R Kates; Raoul Belzeaux; Tiffany Busa; Nicole Philip; Linda E Campbell; Kathryn L McCabe; Stephen R Hooper; Kelly Schoch; Vandana Shashi; Tony J Simon; Flora Tassone; Celso Arango; David Fraguas; Sixto García-Miñaúr; Jaume Morey-Canyelles; Jordi Rosell; Damià H Suñer; Jasna Raventos-Simic; Michael P Epstein; Nigel M Williams; Anne S Bassett
Journal:  Mol Psychiatry       Date:  2020-02-03       Impact factor: 15.992

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.